C-Type Natriuretic Peptide (CNP) (1-22), human (TFA),a 1-22 fragment of CNP, is a natriuretic peptide receptor B ( NPR-B ) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor In Vitro C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) (0.01, 0.1, 1, 10, 100, 1000 nM) increases cGMP production in CHO cells expressing human NPR-B in a concentration-dependent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo PK parameters of CNP immunoreactivity after a single intravenous administration of C-Type Natriuretic Peptide (CNP) (1-22), human : Dose (nM/kg) AUC 0-∞ (pM·min/mL) MRT 0-∞ (min) T 1/2 (min) CL tot (mL/min/kg) Vd ss (mL/kg) 20 320±54 1.02±0.18 1.42±0.45 63.9±11.9 64.2±5.1 PK parameters of CNP immunoreactivity after a single subcutaneous administration of C-Type Natriuretic Peptide (CNP) (1-22), human : Dose (nM/kg) Cmax (pM/mL) Tmax (min) AUC 0-∞ (pM·min/mL) MRT 0-∞ (min) T 1/2 (min) BA (%) 50 9.02±3.74 5.0±0.0 152±73 13.9±3.4 10.0±5.0 19±9 Each value represents the mean±SD of 3 rats. MRT=mean residence time, CL tot =total clearance, T 1/2 =half-life period, BA=bioavailability. i.c.v. administration of C-Type Natriuretic Peptide (CNP) (1-22) in a dose of 2 nM induces an increase in the severity of picrotoxin-kindled convulsions 24 and 48 hrs after application of the peptide. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:NPR-B